Ultragenyx cuts staff after another study fails
The rare-disease company plans a workforce reduction and lower research spending after program setbacks, while maintaining selected late-stage studies.
TL;DR
- Ultragenyx said it expects to reduce its workforce by about 20%, to approximately 1,000 employees, as part of a broader expense-reduction plan.
- The company and coverage linked the retrenchment to clinical-program setbacks, including a failed Phase 3 study of apazunersen for Angelman syndrome.
- Ultragenyx says it will prioritize selected programs and targets profitability in 2027; the commercial and clinical outcomes of those programs remain uncertain.
Ultragenyx announced a new cost-reduction plan alongside its third-quarter results. The company said it expects to reduce headcount by approximately 20%, leaving a workforce of about 1,000, and expects substantially lower research-and-development expenses in 2027 than in 2025. [1] [2] [3]
The move follows setbacks across the pipeline, including the Phase 3 Aspire study of apazunersen, also known as GTX-102, for Angelman syndrome. Fierce Biotech reported that the study missed its primary endpoint and that the company was winding down the program. [1] [2]
Ultragenyx said it plans to concentrate spending on selected programs, including its Phase 3 DTX301 study, and to assess next steps for other candidates. The company reaffirmed a target of reaching profitability in 2027, a forward-looking goal rather than a confirmed result. [1] [2]
The reporting does not establish whether the cost reductions will be sufficient to achieve that target or whether the remaining clinical programs will succeed. The workforce reduction and portfolio changes are company plans; their effects on trial timelines and development capacity remain to be seen. [1] [2]
Why it matters
The restructuring shows how clinical setbacks can quickly change capital allocation at a rare-disease company, shifting resources toward a smaller set of programs. The stated profitability target depends on execution and future clinical data that are not yet available.
Editor's note
Workforce and pipeline details are attributed to the company and Fierce Biotech. Clinical outcomes are not extrapolated.